Michael Makris/LinkedIn
Dec 18, 2025, 23:25
Michael Makris: Excellent Article in This Week’s NEJM Explains Word Estimand Clearly
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
“Do you know what is an “estimand”?
I had never heard of the word until today, but this excellent article in this week’s New England Journal of Medicine (NEJM) explains it clearly.
Essentially, it is the effect of actually taking a drug in a randomised trial. Although simplistically attractive there are good reasons why Intention to Treat (ITT) analysis should remain the gold standard. I can see estimands being used increasingly by manufacturers and sponsored speakers at meetings.”
Discover the latest in Hemostasis Today.
-
Jul 7, 2026, 23:20Balaji Balagani: Exploring Pulmonary Embolism
-
Jul 7, 2026, 23:03Roxana González Mazarío: The Phenotype-Specific Cardiovascular Risks in AAV
-
Jul 7, 2026, 22:52Harry Spoelstra: LongC0VID Still has Zero Proven Treatments
-
Jul 7, 2026, 22:39Satya K. Morar: Acute Portal Vein Thrombosis as an Exceptionally Rare Complication of Liver Biopsy in CVID
-
Jul 7, 2026, 22:23Aravind Palraj: Antiphospholipid Syndrome is not Just ‘Start Warfarin and Follow INR’
-
Jul 7, 2026, 20:59William Aird: An Unlucky Turn Into the Renal Artery
-
Jul 7, 2026, 20:58Chokri Ben Lamine: The Two-Hit Model of TRALI
-
Jul 7, 2026, 20:57New Issue of Blood Out Now – Blood Journals Portfolio
-
Jul 7, 2026, 20:56Priyadarshini Ramakrishnan: Schistocytes – The Most “Misleading Heroes” in a Peripheral Smear